NAS10026,990+1.35%S&P7,377+0.31%GOLD$4,075−0.94%BTC$75,727−0.03%VIX25.64−9.01%latest tape · as of 18:05 UTC
The Screen · Consumer Defensive · Packaged Foods
JBSJBS NV
JBS · the NYSE · USD · Market cap $40.1B · 283,000 employees
JBS N.V., together with its subsidiaries, engages in the processing of animal proteins, encompassing activities related to beef, pork, lamb, and poultry worldwide.
FAIL · Does not pass the screen
12.48 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 18:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price12.48 USD at the 6 Nov 2026 close
Our value readUndervalued vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.09, read 2026-11-02
Ethical does not pass the values gate
Price12.48 USD
Fair value19.52
Ethical score70.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup10.86+14.9% to today ✓Markdown gives way to Markup first Markup read since August
2026-10-02Read Markdown10.86+14.9% to today Distribution gives way to Markdown after a 23% slide in 4 weeks
2026-09-02Read Distribution14.05-11.2% to today ✓Markup gives way to Distribution first Distribution read since July
2026-08-03Read Markup13.55-7.9% to today Distribution gives way to Markup after an 8% rise in 5 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
JBS NV holds its Markup at $12.48. Consolidating, no directional conviction, held for 68 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 68 days
Price at the screen
$12.48
Valuation
11.40 trailing · 8.72 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
50.62%
Below 33%
Interest-bearing debt is 50.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.10%
Below 33%
Cash held in interest-bearing accounts and securities is 0.1% of assets, under the one-third limit.
Pass
Receivables
19.48%
Below 49%
Money owed to the company is 19.5% of assets, under the 49% limit.
Pass
Revenue purity
0.48%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
JBS's business is in a permissible area, but its interest-bearing debt is about 51% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when JBS's ethical verdict changes
Today JBS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 34% discount to our $19.52 fair value, narrow competitive moat, 13.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 36.1% discount to the base estimate.
Where our models see it going: fair-value estimate $19.52, with a range of $19.52 to $25.60, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Global meat plants priced like broken assets
Picture the supply chain behind every supermarket sausage or takeaway burger. JBS runs the plants that turn cattle, pigs and chickens into packaged protein across dozens of countries. The shares sit at an 83 percent discount to our fair value while revenue climbs 11 percent and return on equity hits 22 percent.
A forward multiple of 6.8 times and a narrow moat still leave room for solid cash generation in a defensive category. Fourteen analysts carry a buy consensus with a median target of 19 dollars, and the business clears our ethical screen.
Low single-digit margins and commodity price swings create real cyclical risk. Peak earnings can flatter the multiple and turn an apparent bargain into a trap. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Netherlands and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
JBS trades on the NYSE (the company is based in Netherlands). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup$12.49-3.2%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (15 analysts) rates it strong buy, with a mean price target of $19.
2026-10-25Markup$12.90-0.2%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (15 analysts) rates it strong buy, with a mean price target of $19.
2026-10-18Markup$12.93+19.1%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (15 analysts) rates it strong buy, with a mean price target of $19.
2026-10-11Markup · changed$10.86+0.0%Entry 7
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (15 analysts) rates it strong buy, with a mean price target of $19.
2026-10-02Markdown · changed$10.86-22.7%Entry 6
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 22.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (15 analysts) rates it strong buy, with a mean price target of $19.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (15 analysts) rates it strong buy, with a mean price target of $19.
2026-08-03Markup · changed$13.55+8.1%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (15 analysts) rates it strong buy, with a mean price target of $19.
2026-07-18Distribution$12.54+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (15 analysts) rates it strong buy, with a mean price target of $19.
2026-07-03Distribution$12.54+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$12.54Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.